The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects
Study Details
Study Description
Brief Summary
To determine the dose-response relationship for Clobex TM (clobetasol propionate) Lotion, 0.05%. This information will be used to estimate the ED50, D1, D2 parameters for use in a full bioequivalence study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Study Type: Interventional Study Design: Randomized, open label, one period, dose response, vasoconstrictor assay study.
Official Title: Dose Response of Clobex 0.05% Lotion
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
ยท Vasoconstrictor Response
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A Clobex TM 0.05% Lotion, single exposure |
Drug: Clobex TM (Clobetasol) 0.05% Lotion, single exposure
Subjects received Galderma Laboratories, L.P. formulated products
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Vasoconstriction response [24 hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Non-tobacco-using female subjects, 18 to 50 years of age, inclusive.
-
A demonstrated blanching response to Clobex TM (clobetasol propionate) Lotion, 0.05 %.
-
A body mass index (BMI) 30 kg/m2 or less as calculated according to Novum Standard Operating Procedures.
-
Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator.
-
Signed and dated informed consent form which meets all criteria of current FDA regulations.
Exclusion Criteria:
-
History of allergy to any systemic or topical corticosteroid (including clobetasol) or to any cream, lotion, ointment, gel, cotton, soap, cosmetic, rubber, or tape, which in the opinion of the Investigator would compromise the safety of the subject or the study.
-
Presence of any skin condition or coloration that would interfere with placement of test sites or the response or assessment of skin blanching.
-
Significant history or current evidence of chronic infectious disease, system disorder (especially hypertension or circulatory disease), or organ dysfunction.
-
Presence of a medical condition requiring regular treatment with prescription drugs.
-
Drug or alcohol addiction requiring treatment (in-patient or out-patient) in the 12 months prior to dosing.
-
Use of any topical dermatological drug therapy (including topical corticosteroids) on the flexor surface of the ventral forearms in the 30 days prior to dosing.
-
Use of any tobacco products in the 30 days prior to dosing.
-
Receipt of any drug as part of a research study within 30 days prior to initial study dosing.
-
Pregnant or lactating.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novum Pharmaceutical Research Services | Houston | Texas | United States | 77042-4712 |
Sponsors and Collaborators
- Actavis Inc.
Investigators
- Principal Investigator: Soran Hong,, M.D., Novum Pharmaceutical Research Services
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10504909